{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:27:09Z","timestamp":1770514029805,"version":"3.49.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1097\/ftd.0000000000000202","type":"journal-article","created":{"date-parts":[[2015,2,27]],"date-time":"2015-02-27T13:50:00Z","timestamp":1425045000000},"page":"689-694","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of the QMS Analyzer With HPLC-UV for the Quantification of Lamotrigine Concentrations in Human Plasma Samples"],"prefix":"10.1097","volume":"37","author":[{"given":"Sara","family":"Baldelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Castoldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin","family":"Charbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Fucile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20-20210129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000026527","article-title":"Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder.","volume":"38","author":"Xie","year":"1998","journal-title":"Neuropsychobiology"},{"key":"R2-20-20210129","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/pds.1690","article-title":"Trends and changes in the clinical use of lamotrigine.","volume":"18","author":"Reimers","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R3-20-20210129","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2125.1997.00594.x","article-title":"Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data.","volume":"43","author":"Hussein","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"R4-20-20210129","first-page":"1061","article-title":"Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed Clin Pharmacokinet.","volume":"45","author":"Johannessen","year":"2006","journal-title":""},{"key":"R5-20-20210129","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/01.ftd.0000179852.39717.3e","article-title":"Can pharmacokinetic variability be controlled for the patients benefit The place of TDM for new AEDs.","volume":"27","author":"Johannessen","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R6-20-20210129","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.eplepsyres.2005.06.004","article-title":"Individual changes in lamotrigine plasma concentrations during pregnancy.","volume":"65","author":"Petrenaite","year":"2005","journal-title":"Epilepsy Res"},{"key":"R7-20-20210129","first-page":"791","article-title":"Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful CNS Drugs.","volume":"20","author":"Adab","year":"2006","journal-title":""},{"key":"R8-20-20210129","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.19.6.437.31052","article-title":". Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs.","volume":"19","author":"Chen","year":"1999","journal-title":"Pharmacotherapy"},{"key":"R9-20-20210129","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00007691-199706000-00002","article-title":". The influence of dosage, age and comedication on steady-state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response.","volume":"19","author":"Bartoli","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R10-20-20210129","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003088-200645040-00002","article-title":"Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age.","volume":"45","author":"Perucca","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R11-20-20210129","first-page":"25","article-title":". Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis.","volume":"19","author":"Fillastre","year":"1993","journal-title":"Drug Exp Clin Res"},{"key":"R12-20-20210129","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1046\/j.1365-2125.2001.01389.x","article-title":". Influence of cirrhosis on lamotrigine pharmacokinetics.","volume":"51","author":"Marcellin","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R13-20-20210129","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0920-1211(01)00305-9","article-title":". Lamotrigine plasma levels reduced by oral contraceptives.","volume":"47","author":"Sabers","year":"2001","journal-title":"Epilepsy Res"},{"key":"R14-20-20210129","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/archneur.62.9.1432","article-title":". Effect of antiepileptic drug comedication on lamotrigine clearance.","volume":"62","author":"Weintraub","year":"2005","journal-title":"Arch Neurol"},{"key":"R15-20-20210129","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/01.ftd.0000179854.16846.67","article-title":"The pharmacokinetics and interactions of new antiepileptic drugs: an overview.","volume":"27","author":"Bialer","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R16-20-20210129","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1684\/j.1950-6945.2002.tb00436.x","article-title":". Prospective study on concentration-efficacy and concentration-toxicity: correlations with lamotrigine serum levels.","volume":"4","author":"Froscher","year":"2002","journal-title":"Epileptic Disord"},{"key":"R17-20-20210129","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":". Antiepileptic drugsbest practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies.","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R18-20-20210129","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":". AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"R19-20-20210129","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/01.ftd.0000245779.64080.30","article-title":"Determination of lamotrigine and its metabolites in human plasma by liquid chromatography-mass spectrometry.","volume":"28","author":"Beck","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R20-20-20210129","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10072-010-0257-x","article-title":". Determination of lamotrigine in human serum by high-performance liquid chromatography-tandem mass spectrometry.","volume":"31","author":"Lee","year":"2010","journal-title":"Neurol Sci"},{"key":"R21-20-20210129","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/FTD.0000000000000123","article-title":". Quantification of lamotrigine in patient plasma utilizing a fast liquid chromatography-tandem mass spectrometry method with backflush technology.","volume":"37","author":"Wong","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R22-20-20210129","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1515\/cclm-2014-0472","article-title":". Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots.","volume":"53","author":"Baldelli","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"R23-20-20210129","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0378-4347(99)00043-2","article-title":". Determination of lamotrigine in human plasma by high-performance liquid chromatography.","volume":"727","author":"Angelis-Stoforidis","year":"1999","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R24-20-20210129","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jchromb.2009.11.039","article-title":". Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy.","volume":"878","author":"Contin","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R25-20-20210129","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/00007691-199708000-00016","article-title":". Analysis of the antiepileptic phenyltriazine compound lamotrigine using gas chromatography with nitrogen phosphorus detection.","volume":"19","author":"Watelle","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R26-20-20210129","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0378-4347(97)00064-9","article-title":"Lamotrigine analysis in plasma by gas chromatography-mass spectrometry after conversion to a tert.-butyldimethylsilyl derivative.","volume":"693","author":"Dasgupta","year":"1997","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R28-20-20210129","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/clinchem\/46.1.100","article-title":"General deming regression for estimating systematic bias and its confidence interval in method-comparison studies.","volume":"46","author":"Martin","year":"2000","journal-title":"Clin Chem"},{"key":"R30-20-20210129","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement.","volume":"1","author":"Bland","year":"1986","journal-title":"Lancet"},{"key":"R31-20-20210129","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/clinchem\/48.5.799","article-title":". Application of the Bland-Altman plot for interpretation of method-comparison studies: a critical investigation of its practice.","volume":"48","author":"Dewitte","year":"2002","journal-title":"Clin Chem"},{"key":"R32-20-20210129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/096228029900800204","article-title":"Measuring agreement in method comparison studies.","volume":"8","author":"Bland","year":"1999","journal-title":"Stat Methods Med Res"},{"key":"R33-20-20210129","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ijnurstu.2009.10.001","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement.","volume":"47","author":"Bland","year":"2010","journal-title":"Int J Nurs Stud"},{"key":"R34-20-20210129","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jchromb.2011.09.041","article-title":"Therapeutic drug monitoring and LC-MSMS.","volume":"883-","author":"Adaway","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R35-20-20210129","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1586\/14737175.8.6.929","article-title":"Value of therapeutic drug monitoring in epilepsy.","volume":"8","author":"Johannessen","year":"2008","journal-title":"Expert Rev Neurother"},{"key":"R36-20-20210129","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/FTD.0000000000000133","article-title":". Evaluation of QMS everolimus assay using Indiko analyzer: comparison with an ultra-performance liquid chromatography tandem mass spectrometry (UPLCMSMS) method.","volume":"37","author":"Buthiau","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R37-20-20210129","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.cca.2011.06.009","article-title":". A comparison of two FDA approved lamotrigine immunoassays with ultra-high performance liquid chromatography tandem mass spectrometry.","volume":"412","author":"Juenke","year":"2011","journal-title":"Clin Chim Acta"},{"key":"R38-20-20210129","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/bmc.1515","article-title":". A rapid and simple assay for lamotrigine in serumplasma by HPLC, and comparison with an immunoassay.","volume":"25","author":"Morgan","year":"2011","journal-title":"Biomed Chromatogr"},{"key":"R39-20-20210129","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/FTD.0b013e31818580b3","article-title":"Seradyn quantitative microsphere system lamotrigine immunoassay on a Hitachi 911 analyzer compared with HPLC-UV.","volume":"30","author":"Westley","year":"2008","journal-title":"Ther Drug Monit"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T13:32:25Z","timestamp":1717767145000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201510000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000202","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}